

BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation
Against:

Michael Theodore Lardon, M.D.

Physician's and Surgeon's
Certificate No. A 48664

Respondent.

Case No.: 800-2017-035372


DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on April 15, 2022.

IT IS SO ORDERED: March 16, 2022.

MEDICAL BOARD OF CALIFORNIA



Laurie Rose Lubiano, J.D., Chair
Panel A

1 ROB BONTA
Attorney General of California
2 MATTHEW M. DAVIS
Supervising Deputy Attorney General
3 GIOVANNI F. MEJIA
Deputy Attorney General
4 State Bar No. 309951
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9072
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9
10 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
11 **DEPARTMENT OF CONSUMER AFFAIRS**
12 **STATE OF CALIFORNIA**

13 In the Matter of the Accusation Against:

Case No. 800-2017-035372

14 **MICHAEL THEODORE LARDON, M.D.**
15 **3750 Convoy Street, Suite 318**
San Diego, CA 92111

OAH No. 2021020353

16 **Physician's and Surgeon's Certificate**
17 **No. A 48664,**

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER**

18 Respondent.

19 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
20 entitled proceedings that the following matters are true:

21 **PARTIES**

22 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of
23 California (Board). He brought this action solely in his official capacity and is represented in this
24 matter by Rob Bonta, Attorney General of the State of California, by Giovanni F. Mejia, Deputy
25 Attorney General.

26 2. Respondent Michael Theodore Lardon, M.D. (Respondent) is represented in this
27 proceeding by attorney Robert W. Frank, Esq. whose address is: Neil, Dymott, Frank, McCabe &
28 Hudson APLC, 110 West A Street, Suite 1200, San Diego, CA 92101.

1 2017-035372, a true and correct copy of which is attached hereto as exhibit A, and that he has
2 thereby subjected his Physician's and Surgeon's Certificate, No. A 48664 to disciplinary action.

3 10. Respondent agrees that his Physician's and Surgeon's License is subject to discipline
4 and he agrees to be bound by the Board's probationary terms as set forth in the Disciplinary Order
5 below.

6 11. Respondent agrees that if he ever petitions for early termination or modification of
7 probation, or if an accusation and/or petition to revoke probation is filed against him before the
8 Board, all of the charges and allegations contained in Accusation No. 800-2017-035372 shall be
9 deemed true, correct and fully admitted by respondent for purposes of any such proceeding or any
10 other licensing proceeding involving Respondent in the State of California.

11 CONTINGENCY

12 12. This stipulation shall be subject to approval by the Medical Board of California.
13 Respondent understands and agrees that counsel for Complainant and the staff of the Medical
14 Board of California may communicate directly with the Board regarding this stipulation and
15 settlement, without notice to or participation by Respondent or his counsel. By signing the
16 stipulation, Respondent understands and agrees that he may not withdraw his agreement or seek
17 to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails
18 to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary
19 Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal
20 action between the parties, and the Board shall not be disqualified from further action by having
21 considered this matter.

22 ADDITIONAL PROVISIONS

23 13. This Stipulated Settlement and Disciplinary Order is intended by the parties herein to
24 be an integrated writing representing the complete, final and exclusive embodiment of the
25 agreements of the parties in the above-entitled matter.

26 14. The parties understand and agree that Portable Document Format (PDF) and facsimile
27 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile
28 signatures thereto, shall have the same force and effect as the originals.

1 or its designee, be accepted towards the fulfillment of this condition if the course would have
2 been approved by the Board or its designee had the course been taken after the effective date of
3 this Decision.

4 Respondent shall submit a certification of successful completion to the Board or its
5 designee not later than 15 calendar days after successfully completing the course, or not later than
6 15 calendar days after the effective date of the Decision, whichever is later.

7 3. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective
8 date of this Decision, Respondent shall enroll in a course in medical record keeping approved in
9 advance by the Board or its designee. Respondent shall provide the approved course provider
10 with any information and documents that the approved course provider may deem pertinent.
11 Respondent shall participate in and successfully complete the classroom component of the course
12 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully
13 complete any other component of the course within one (1) year of enrollment. The medical
14 record keeping course shall be at Respondent's expense and shall be in addition to the Continuing
15 Medical Education (CME) requirements for renewal of licensure.

16 A medical record keeping course taken after the acts that gave rise to the charges in the
17 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
18 or its designee, be accepted towards the fulfillment of this condition if the course would have
19 been approved by the Board or its designee had the course been taken after the effective date of
20 this Decision.

21 Respondent shall submit a certification of successful completion to the Board or its
22 designee not later than 15 calendar days after successfully completing the course, or not later than
23 15 calendar days after the effective date of the Decision, whichever is later.

24 4. MONITORING - PRACTICE. Within 30 calendar days of the effective date of this
25 Decision, Respondent shall submit to the Board or its designee for prior approval as a practice
26 monitor(s), the name and qualifications of one or more licensed physicians and surgeons whose
27 licenses are valid and in good standing, and who are preferably American Board of Medical
28 Specialties (ABMS) certified. A monitor shall have no prior or current business or personal

1 relationship with Respondent, or other relationship that could reasonably be expected to
2 compromise the ability of the monitor to render fair and unbiased reports to the Board, including
3 but not limited to any form of bartering, shall be in Respondent's field of practice, and must agree
4 to serve as Respondent's monitor. Respondent shall pay all monitoring costs.

5 The Board or its designee shall provide the approved monitor with copies of the Decision(s)
6 and Accusation(s), and a proposed monitoring plan. Within 15 calendar days of receipt of the
7 Decision(s), Accusation(s), and proposed monitoring plan, the monitor shall submit a signed
8 statement that the monitor has read the Decision(s) and Accusation(s), fully understands the role
9 of a monitor, and agrees or disagrees with the proposed monitoring plan. If the monitor disagrees
10 with the proposed monitoring plan, the monitor shall submit a revised monitoring plan with the
11 signed statement for approval by the Board or its designee.

12 Within 60 calendar days of the effective date of this Decision, and continuing throughout
13 probation, Respondent's practice shall be monitored by the approved monitor. Respondent shall
14 make all records available for immediate inspection and copying on the premises by the monitor
15 at all times during business hours and shall retain the records for the entire term of probation.

16 If Respondent fails to obtain approval of a monitor within 60 calendar days of the effective
17 date of this Decision, Respondent shall receive a notification from the Board or its designee to
18 cease the practice of medicine within three (3) calendar days after being so notified. Respondent
19 shall cease the practice of medicine until a monitor is approved to provide monitoring
20 responsibility.

21 The monitor(s) shall submit a quarterly written report to the Board or its designee which
22 includes an evaluation of Respondent's performance, indicating whether Respondent's practices
23 are within the standards of practice of medicine, and whether Respondent is practicing medicine
24 safely, billing appropriately or both. It shall be the sole responsibility of Respondent to ensure
25 that the monitor submits the quarterly written reports to the Board or its designee within 10
26 calendar days after the end of the preceding quarter.

27 If the monitor resigns or is no longer available, Respondent shall, within 5 calendar days of
28 such resignation or unavailability, submit to the Board or its designee, for prior approval, the

1 name and qualifications of a replacement monitor who will be assuming that responsibility within
2 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within 60
3 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a
4 notification from the Board or its designee to cease the practice of medicine within three (3)
5 calendar days after being so notified. Respondent shall cease the practice of medicine until a
6 replacement monitor is approved and assumes monitoring responsibility.

7 In lieu of a monitor, Respondent may participate in a professional enhancement program
8 approved in advance by the Board or its designee that includes, at minimum, quarterly chart
9 review, semi-annual practice assessment, and semi-annual review of professional growth and
10 education. Respondent shall participate in the professional enhancement program at Respondent's
11 expense during the term of probation.

12 5. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the
13 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the
14 Chief Executive Officer at every hospital where privileges or membership are extended to
15 Respondent, at any other facility where Respondent engages in the practice of medicine,
16 including all physician and locum tenens registries or other similar agencies, and to the Chief
17 Executive Officer at every insurance carrier which extends malpractice insurance coverage to
18 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15
19 calendar days.

20 This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

21 6. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE
22 NURSES. During probation, Respondent is prohibited from supervising physician assistants and
23 advanced practice nurses.

24 7. OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules
25 governing the practice of medicine in California and remain in full compliance with any court
26 ordered criminal probation, payments, and other orders.

27 ////

28 ////

1 8. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations
2 under penalty of perjury on forms provided by the Board, stating whether there has been
3 compliance with all the conditions of probation.

4 Respondent shall submit quarterly declarations not later than 10 calendar days after the end
5 of the preceding quarter.

6 9. GENERAL PROBATION REQUIREMENTS.

7 Compliance with Probation Unit

8 Respondent shall comply with the Board's probation unit.

9 Address Changes

10 Respondent shall, at all times, keep the Board informed of Respondent's business and
11 residence addresses, email address (if available), and telephone number. Changes of such
12 addresses shall be immediately communicated in writing to the Board or its designee. Under no
13 circumstances shall a post office box serve as an address of record, except as allowed by Business
14 and Professions Code section 2021, subdivision (b).

15 Place of Practice

16 Respondent shall not engage in the practice of medicine in Respondent's or patient's place
17 of residence, unless the patient resides in a skilled nursing facility or other similar licensed
18 facility.

19 License Renewal

20 Respondent shall maintain a current and renewed California physician's and surgeon's
21 license.

22 Travel or Residence Outside California

23 Respondent shall immediately inform the Board or its designee, in writing, of travel to any
24 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty
25 (30) calendar days.

26 In the event Respondent should leave the State of California to reside or to practice
27 Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of
28 departure and return.

1 10. INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be
2 available in person upon request for interviews either at Respondent's place of business or at the
3 probation unit office, with or without prior notice throughout the term of probation.

4 11. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or
5 its designee in writing within 15 calendar days of any periods of non-practice lasting more than
6 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is
7 defined as any period of time Respondent is not practicing medicine as defined in Business and
8 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct
9 patient care, clinical activity or teaching, or other activity as approved by the Board. If
10 Respondent resides in California and is considered to be in non-practice, Respondent shall
11 comply with all terms and conditions of probation. All time spent in an intensive training program
12 which has been approved by the Board or its designee shall not be considered non-practice and
13 does not relieve Respondent from complying with all the terms and conditions of probation.
14 Practicing medicine in another state of the United States or Federal jurisdiction while on
15 probation with the medical licensing authority of that state or jurisdiction shall not be considered
16 non-practice. A Board-ordered suspension of practice shall not be considered as a period of non-
17 practice.

18 In the event Respondent's period of non-practice while on probation exceeds 18 calendar
19 months, Respondent shall successfully complete the Federation of State Medical Boards's Special
20 Purpose Examination, or, at the Board's discretion, a clinical competence assessment program
21 that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model
22 Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

23 Respondent's period of non-practice while on probation shall not exceed two (2) years.

24 Periods of non-practice will not apply to the reduction of the probationary term.

25 Periods of non-practice for a Respondent residing outside of California will relieve
26 Respondent of the responsibility to comply with the probationary terms and conditions with the
27 exception of this condition and the following terms and conditions of probation: Obey All Laws;

28 ////

1 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or
2 Controlled Substances; and Biological Fluid Testing.

3 12. COMPLETION OF PROBATION. Respondent shall comply with all financial
4 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the
5 completion of probation. Upon successful completion of probation, Respondent's certificate shall
6 be fully restored.

7 13. VIOLATION OF PROBATION. Failure to fully comply with any term or condition
8 of probation is a violation of probation. If Respondent violates probation in any respect, the
9 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and
10 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,
11 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have
12 continuing jurisdiction until the matter is final, and the period of probation shall be extended until
13 the matter is final.

14 14. LICENSE SURRENDER. Following the effective date of this Decision, if
15 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy
16 the terms and conditions of probation, Respondent may request to surrender his or her license.
17 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in
18 determining whether or not to grant the request, or to take any other action deemed appropriate
19 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent
20 shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its
21 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject
22 to the terms and conditions of probation. If Respondent re-applies for a medical license, the
23 application shall be treated as a petition for reinstatement of a revoked certificate.

24 15. PROBATION MONITORING COSTS. Respondent shall pay the costs associated
25 with probation monitoring each and every year of probation, as designated by the Board, which
26 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of
27 California and delivered to the Board or its designee no later than January 31 of each calendar
28 year.

1 16. FUTURE ADMISSIONS CLAUSE. If Respondent should ever apply or reapply for a
2 new license or certification, or petition for reinstatement of a license, by any other health care
3 licensing action agency in the State of California, all of the charges and allegations contained in
4 Accusation No. 800-2017-035372 shall be deemed to be true, correct, and admitted by
5 Respondent for the purpose of any Statement of Issues or any other proceeding seeking to deny or
6 restrict license.

7 ////
8 ////
9 ////
10 ////
11 ////
12 ////
13 ////
14 ////
15 ////
16 ////
17 ////
18 ////
19 ////
20 ////
21 ////
22 ////
23 ////
24 ////
25 ////
26 ////
27 ////
28 ////

ACCEPTANCE


I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Robert W. Frank, Esq. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: 12/29/21


MICHAEL THEODORE LARDON, M.D.
Respondent

I have read and fully discussed with Respondent Michael Theodore Lardon, M.D. the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.


DATED: 12-30-21


ROBERT W. FRANK, ESQ.
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: December 30, 2021

Respectfully submitted,
ROB BONTA
Attorney General of California
MATTHEW M. DAVIS
Supervising Deputy Attorney General

GIOVANNI F. MEJIA
Deputy Attorney General
Attorneys for Complainant

SD2020301752

Exhibit A

1 XAVIER BECERRA
Attorney General of California
2 MATTHEW M. DAVIS
Supervising Deputy Attorney General
3 GIOVANNI F. MEJIA
Deputy Attorney General
4 State Bar No. 309951
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9072
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

Case No. 800-2017-035372

Michael Theodore Lardon, M.D.
3750 Convoy Street, Suite 318
San Diego, CA 92111

A C C U S A T I O N

**Physician's and Surgeon's Certificate
No. A 48664,**

Respondent.

PARTIES

1. William Prasifka (Complainant) brings this Accusation solely in his official capacity as the Executive Director of the Medical Board of California, Department of Consumer Affairs (Board).
2. On or about September 17, 1990, the Medical Board issued Physician's and Surgeon's Certificate No. A 48664 to Michael Theodore Lardon, M.D. (Respondent). The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought herein and will expire on May 31, 2022, unless renewed.

///
///

1 **JURISDICTION**

2 3. This Accusation is brought before the Board, under the authority of the following
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise
4 indicated.

5 4. Section 2227, subdivision (a) of the Code states:

6 A licensee whose matter has been heard by an administrative law judge of the
7 Medical Quality Hearing Panel as designated in Section 11371 of the Government
8 Code, or whose default has been entered, and who is found guilty, or who has entered
9 into a stipulation for disciplinary action with the board, may, in accordance with the
10 provisions of this chapter:

11 (1) Have his or her license revoked upon order of the board.

12 (2) Have his or her right to practice suspended for a period not to exceed one
13 year upon order of the board.

14 (3) Be placed on probation and be required to pay the costs of probation
15 monitoring upon order of the board.

16 (4) Be publicly reprimanded by the board. The public reprimand may include a
17 requirement that the licensee complete relevant educational courses approved by the
18 board.

19 (5) Have any other action taken in relation to discipline as part of an order of
20 probation, as the board or an administrative law judge may deem proper.

21 5. Section 2234 of the Code states, in pertinent part:

22 The board shall take action against any licensee who is charged with
23 unprofessional conduct. In addition to other provisions of this article, unprofessional
24 conduct includes, but is not limited to, the following:

25 (a) Violating or attempting to violate, directly or indirectly, assisting in or
26 abetting the violation of, or conspiring to violate any provision of this chapter.

27 (b) Gross negligence.

28 (c) Repeated negligent acts. To be repeated, there must be two or more
negligent acts or omissions. An initial negligent act or omission followed by a
separate and distinct departure from the applicable standard of care shall constitute
repeated negligent acts.

(1) An initial negligent diagnosis followed by an act or omission medically
appropriate for that negligent diagnosis of the patient shall constitute a single
negligent act.

(2) When the standard of care requires a change in the diagnosis, act, or
omission that constitutes the negligent act described in paragraph (1), including, but
not limited to, a reevaluation of the diagnosis or a change in treatment, and the

1 licensee's conduct departs from the applicable standard of care, each departure
2 constitutes a separate and distinct breach of the standard of care.

3

4 6. Section 2242, subdivision (a) of the Code states:

5 Prescribing, dispensing, or furnishing dangerous drugs as defined in
6 Section 4022 without an appropriate prior examination and a medical indication,
7 constitutes unprofessional conduct. An appropriate prior examination does not require
8 a synchronous interaction between the patient and the licensee and can be achieved
9 through the use of telehealth, including, but not limited to, a self-screening tool or a
10 questionnaire, provided that the licensee complies with the appropriate standard of
11 care.

12 7. Section 725, subdivision (a) of the Code states:

13 Repeated acts of clearly excessive prescribing, furnishing, dispensing, or
14 administering of drugs or treatment, repeated acts of clearly excessive use of
15 diagnostic procedures, or repeated acts of clearly excessive use of diagnostic or
16 treatment facilities as determined by the standard of the community of licensees is
17 unprofessional conduct for a physician and surgeon, dentist, podiatrist, psychologist,
18 physical therapist, chiropractor, optometrist, speech-language pathologist, or
19 audiologist.

20 8. Section 2266 of the Code states:

21 The failure of a physician and surgeon to maintain adequate and accurate
22 records relating to the provision of services to their patients constitutes unprofessional
23 conduct.

24 **FIRST CAUSE FOR DISCIPLINE**

25 **(Gross Negligence)**

26 9. Respondent Michael Theodore Lardon, M.D. has subjected his Physician's and
27 Surgeon's Certificate No. A 48664 to disciplinary action under sections 2227 and 2234, as
28 defined by section 2234, subdivision (b), of the Code in that he committed gross negligence in his
care and treatment of one or more patients. The circumstances are as follows:

10 10. At all times pertinent to the patient care and treatment described herein, Respondent
11 operated a private psychiatry practice in or around San Diego, California.

12 ///

13 ///

14 ///

15 ///

Patient A

11. On or about April 23, 2015, "Patient A"¹ presented to Respondent for the first time. In his progress note for this clinical encounter, Respondent documented a medical history including, but not limited to, multiple gastrointestinal ailments, high blood pressure, hyperlipidemia, migraines, muscle spasms and pain in her upper and lower extremities. Respondent documented diagnoses including, but not limited to, major depressive disorder and chronic pain disorder, as well as a history of severe ulcer, gastrointestinal disease, chronic pain syndrome secondary to atypical fibromyalgia, migraine headaches, and C. difficile infection.

12. In his progress note for the clinical encounter with Patient A on or about April 23, 2015, Respondent further documented that Patient A was receiving pain medications from a neurologist. Respondent documented that Patient A's medications at the time included, but were not limited to, eight Percocet 10/325 mg tablets,² six tizanidine 4 mg pills,³ and 1 mg to 3 mg of Klonopin⁴ per day.

13. In or about June 2015, Patient A's then neurologist advised Patient A or Respondent that he was going to no longer practice neurology. At or shortly after this time, Respondent took over the prescribing of opioid or opiate medications to Patient A.

14. Respondent failed to adequately assess Patient A's chronic pain, fibromyalgia, muscle spasms or other pain-related symptoms or ailment—including, but not limited to, failing to adequately obtain or document vital signs, a physical examination, diagnostic workup, or review

////

¹ Patient true names are not used in the accusation to maintain patient confidentiality. The identity of any patient referenced herein is known to Respondent or will be disclosed to Respondent following Complainant's receipt of a duly-issued request for discovery pursuant to Government Code section 11507.6.

² Percocet is a brand name for the drug combination of oxycodone (2.5 mg, 5 mg, 7.5 mg, or 10 mg) and acetaminophen (325 mg). The "10/325" notation refers to the prescribed strength of each tablet consisting of 10 mg of oxycodone and 325 mg of acetaminophen. It is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b), and a dangerous drug pursuant to Business and Professions Code section 4022. When properly prescribed and indicated, it is used for the treatment of moderate to severe pain.

³ Zanaflex is a brand name for tizanidine. It is a muscle relaxant and a dangerous drug pursuant to Business and Professions Code section 4022.

⁴ Klonopin is a brand name for clonazepam. It is a benzodiazepine, a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.

1 of records from prior treatment providers, or any combination thereof—prior to initiating his
2 chronic prescribing of high-dose opioids or opiates to Patient A.

3 15. Respondent failed to enter into a pain management agreement with or otherwise
4 obtain and document adequate informed consent from Patient A at or near the outset of his
5 prescribing of controlled substances to Patient A for chronic pain.

6 16. In or about July 2015 to December 8, 2015, Respondent issued to Patient A multiple
7 prescriptions for purported monthly supplies of opioid or opiate medications including, but not
8 limited to, prescriptions issued approximately on and for the following dates and dosages:

Date	Drug Name	Strength	Quantity
7/16/2015	Fentanyl ⁵	25 mcg	10
7/16/2015	Percocet	10/325 mg	240
8/10/2015	Percocet	10/325 mg	240
8/10/2015	OxyContin ⁶	20 mg	30
9/3/2015	Percocet	10/325 mg	240
9/3/2015	OxyContin	10 mg	30
9/28/2015	Oxycodone ⁷	10 mg	240
10/19/2015	Oxycodone	10 mg	240
11/12/2015	Oxycodone	10 mg	240
12/7/2015	Oxycodone	10 mg	240

18 17. During this period, the California Controlled Substance Utilization Review and
19 Evaluation System (CURES) lists prescriptions for purported 30-day supplies of 90 Klonopin
20 1 mg tablets issued by healthcare providers other than Respondent and filled or refilled to
21 Patient A on or about August 17, September 18, November 12, and December 8, 2015.

22 ////

23 ////

24 ⁵ Fentanyl is a Schedule II controlled substance pursuant to Health and Safety Code
25 section 11055, subdivision (c), and a dangerous drug pursuant to Business and Professions Code
section 4022.

26 ⁶ OxyContin is a brand name for extended-release oxycodone, a Schedule II controlled
27 substance pursuant to Health and Safety Code section 11055, subdivision (b), and a dangerous
drug pursuant to Business and Professions Code section 4022.

28 ⁷ Oxycodone is a Schedule II controlled substance pursuant to Health and Safety Code
section 11055, subdivision (b), and a dangerous drug pursuant to Business and Professions Code
section 4022.

1 18. Commencing on or about December 7, 2015, if not earlier, Respondent took over the
2 prescribing of Zanaflex to Patient A, on this occasion issuing her a prescription for a purported
3 one-month supply of approximately 180 Zanaflex 4 mg pills.

4 19. Respondent failed to adequately document an assessment of Patient A or the rationale
5 for his prescribing of Zanaflex, or the dosage prescribed, to Patient A.

6 20. On or about December 28, 2015, Respondent issued a Klonopin prescription to
7 Patient A.

8 21. Respondent failed to adequately document a clinical assessment or rationale for his
9 prescribing of Klonopin, or the dosage prescribed, to Patient A.

10 22. Respondent failed to adequately discuss or document discussing with Patient A the
11 risks associated with concomitant use of opioids or opiates and benzodiazepines, or the possibility
12 of prescribing Narcan⁸ to Patient A.

13 23. In or about December 28, 2015 to July 2016, Respondent issued to Patient A multiple
14 prescriptions for purported monthly supplies of oxycodone, Klonopin or Zanaflex including, but
15 not limited to, prescriptions issued approximately on and for the following dates and dosages:

Date	Drug Name	Strength	Quantity
12/28/2015	Oxycodone	10 mg	240
12/28/2015	Klonopin	1 mg	90
1/21/2016	Oxycodone	10 mg	240
1/21/2016	Klonopin	1 mg	90
2/11/2016	Oxycodone	10 mg	240
2/11/2016	Klonopin	1 mg	90
2/11/2016	Zanaflex	4 mg	180
3/3/2016	Oxycodone	10 mg	240
3/31/2016	Oxycodone	10 mg	240
4/21/2016	Oxycodone	10 mg	240

25 ///

26 ///

27 _____
28 ⁸ Narcan is a brand name for naloxone and is commonly used to reverse the effects of
opioid or opiate overdose.

1 24. During this period, the CURES database lists prescriptions for purported 30-day
2 supplies of 90 Klonopin 1 mg tablets issued by a healthcare provider other than Respondent and
3 filled or refilled to Patient A on or about March 9, April 4, April 28 and May 21, 2016.

4 25. In a progress note for a clinical encounter with Patient A on or about May 12, 2016,
5 Respondent documented that he was "going to take over writing the Klonopin [prescriptions]."

6 26. On or about April 28, 2016, Respondent received a "Retrospective Drug Utilization
7 Review Program" notice from an insurance carrier advising, among other things, that Patient A
8 had filled prescriptions issued by Respondent for purported 30-day supplies of 240 oxycodone
9 10 mg tablets on January 23, February 16, and March 10, 2016. The notice further stated that
10 "[c]hronic early refills may be associated with an increased risk of medication abuse/misuse [and]
11 [e]arly refills may also indicate that pain is not well controlled for a patient."

12 27. In or about May 2016 to September 2016, Respondent continued to issue to Patient A
13 multiple prescriptions for purported monthly supplies of oxycodone, Klonopin or Zanaflex
14 including, but not limited to, prescriptions issued approximately on and for the following dates
15 and dosages:

Date	Drug Name	Strength	Quantity
5/12/2016	Oxycodone	10 mg	240
5/12/2016	Klonopin	1 mg	90
5/12/2016	Zanaflex	4 mg	180 (3 refills)
6/9/2016	Oxycodone	10 mg	240
6/9/2016	Klonopin	1 mg	90
6/9/2016	Zanaflex	4 mg	180 (3 refills)
6/30/2016	Oxycodone	10 mg	240
6/30/2016	Klonopin	1 mg	90
7/25/2016	Oxycodone	10 mg	240
7/25/2016	Klonopin	1 mg	90
8/11/2016	Oxycodone	10 mg	240
8/11/2016	Klonopin	1 mg	90
9/8/2016	Oxycodone	10 mg	240
9/8/2016	Klonopin	1 mg	90
9/8/2016	Zanaflex	4 mg	180 (3 refills)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Date	Drug Name	Strength	Quantity
9/29/2016	Oxycodone	10 mg	240
9/29/2016	Klonopin	1 mg	90

28. During this period, on or about July 23, 2016, Respondent received another "Retrospective Drug Utilization Review Program" notice from an insurance carrier advising, among other things, that Patient A had filled prescriptions issued by Respondent for purported 30-day supplies of 240 oxycodone 10 mg tablets on April 2, April 25, May 18, and June 10, 2016. The notice further stated that "[c]hronic early refills may be associated with an increased risk of medication abuse/misuse [and] [e]arly refills may also indicate that pain is not well controlled for a patient."

29. During this period, in a progress note for a clinical encounter with Patient A on or about August 11, 2016, Respondent documented that Patient A had woken up the previous weekend delirious and with a blood pressure of 60/40 mmHg. Respondent documented that paramedics were called and Patient A was taken to the hospital. Respondent documented that eventually Patient A "did leave the hospital [against medical advice] because they didn't give her any of her pain medicine or sleep medicine."

30. In his progress note for a clinical encounter with Patient A on or about October 24, 2016, Respondent documented that Patient A and her spouse stated that another healthcare provider had advised that Patient A would be in more pain due to a recent bout of sepsis. Respondent further documented that he was going to increase the quantities of Patient A's prescriptions because Patient A was running out of medication at the end of the month. Respondent also documented that he was decreasing Patient A's Klonopin prescription to 2.5 mg per day.

////
////
////
////
////

1 31. In or about October and November 2016, Respondent increased his prescribing of the
2 purported monthly supplies of oxycodone and Zanaflex, and decreased his prescribing of
3 Klonopin, to Patient A. Such prescriptions during this period included, without limitation,
4 prescriptions issued approximately on and for the following dates and dosages:

	Date	Drug Name	Strength	Quantity
5				
6	10/24/2016	Oxycodone	10 mg	279
7	10/24/2016	Klonopin	1 mg	75
8	10/24/2016	Zanaflex	4 mg	279
9	11/17/2016	Oxycodone	10 mg	279
10	11/17/2016	Klonopin	1 mg	60
	11/17/2016	Zanaflex	4 mg	279

11 32. On or about November 30, 2016, Respondent received another "Retrospective Drug
12 Utilization Review Program" notice from an insurance carrier advising, among other things, that
13 Patient A had filled prescriptions issued by Respondent for purported 30-day supplies of
14 240 oxycodone 10 mg tablets on July 3, July 26, August 18 and September 10, 2016. The notice
15 further stated that "[c]hronic early refills may be associated with an increased risk of medication
16 abuse/misuse [and] [e]arly refills may also indicate that pain is not well controlled for a patient."
17 On one of the pages of the notice, Respondent documented that Patient A had stated that she had
18 a stockpile of pills and that Respondent wanted Patient A or her spouse to bring the stockpile in.

19 33. In a progress note for a clinical encounter with Patient A on or about December 1,
20 2016, Respondent documented:

21 [Respondent] did get a Drug Utilization Review that stated over the last
22 4 months [Patient A] was filling her oxycodone essentially 1 week early. [Respondent
23 was] unclear about this...[¶]...[Respondent was] going to have [Patient A's spouse]
24 come in [and] bring in any extra meds...."

24 34. In a progress note for a clinical encounter with Patient A on or about December 12,
25 2016, Respondent documented:

26 [Patient A] came in with her husband today. Essentially, had to address
27 the issue of the oxycodone. We very carefully went through the early refills and
28 essentially prior to increasing the number per month from #240 to #270 [Patient A]
was running a deficit and getting them filled early. With that being said, none of that
has happened since. We went through this very carefully with her husband here.

1 35. In or about the following year, Respondent continued to prescribe the increased
2 purported monthly supplies of oxycodone and Zanaflex to Patient A, but ceased to prescribe
3 Klonopin to Patient A for a period of multiple months before resuming in or about October 2017.
4 Respondent's prescriptions of oxycodone, Zanaflex, and Klonopin to Patient A in or about
5 December 2016 to December 2017 included, without limitation, prescriptions issued
6 approximately on and for the following dates and dosages:

Date	Drug Name	Strength	Quantity
12/1/2016	Oxycodone	10 mg	279
12/1/2016	Zanaflex	4 mg	279
12/12/2016	Oxycodone	10 mg	279
12/12/2016	Zanaflex	4 mg	279
12/29/2016	Oxycodone	10 mg	279
12/29/2016	Zanaflex	4 mg	279
1/19/2017	Oxycodone	10 mg	279
1/19/2017	Zanaflex	4 mg	279
2/13/2017	Oxycodone	10 mg	279
2/13/2017	Zanaflex	4 mg	279
3/13/2017	Oxycodone	10 mg	279
3/13/2017	Zanaflex	4 mg	279
4/3/2017	Oxycodone	10 mg	279
4/3/2017	Zanaflex	4 mg	279
5/1/2017	Oxycodone	10 mg	279
5/1/2017	Zanaflex	4 mg	279
5/25/2017	Oxycodone	10 mg	279
5/25/2017	Zanaflex	4 mg	279
6/15/2017	Oxycodone	10 mg	279
6/15/2017	Zanaflex	4 mg	279
7/5/2017	Oxycodone	10 mg	279
7/5/2017	Zanaflex	4 mg	279
7/24/2017	Oxycodone	10 mg	279
7/24/2017	Zanaflex	4 mg	279
8/15/2017	Oxycodone	10 mg	279
8/15/2017	Zanaflex	4 mg	279
9/11/2017	Oxycodone	10 mg	279

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Date	Drug Name	Strength	Quantity
9/11/2017	Zanaflex	4 mg	279
10/2/2017	Oxycodone	10 mg	279
10/2/2017	Klonopin	1 mg	90
10/2/2017	Zanaflex	4 mg	279
10/25/2017	Oxycodone	10 mg	279
11/15/2017	Oxycodone	10 mg	279
11/15/2017	Klonopin	1 mg	90
11/15/2017	Zanaflex	4 mg	279
12/6/2017	Oxycodone	10 mg	279
12/6/2017	Klonopin	1 mg	90
12/6/2017	Zanaflex	4 mg	279

36. In a progress note for a clinical encounter with Patient A on or about December 6, 2017, Respondent documented asking Patient A's spouse to "cut back the oxycodone by 25% during this time to see how [Patient A] does." However, Respondent did not reduce the purported monthly supply of oxycodone he prescribed to Patient A on or about December 6, 2017.

37. Commencing on or about December 27, 2017, Respondent did begin to modify the purported monthly supplies of oxycodone, Klonopin, and Zanaflex he was prescribing to Patient A. Respondent's prescribing of such medications in or around December 27, 2017 to December 5, 2018 included, without limitation, prescriptions issued approximately on and for the following dates and dosages:

Date	Drug Name	Strength	Quantity
12/27/2017	Oxycodone	10 mg	249
12/27/2017	Klonopin	1 mg	60
12/27/2017	Zanaflex	4 mg	279
1/24/2018	Oxycodone	10 mg	249
1/24/2018	Klonopin	1 mg	45
1/24/2018	Zanaflex	4 mg	249
2/14/2018	Oxycodone	10 mg	234
2/14/2018	Klonopin	1 mg	45
2/14/2018	Zanaflex	4 mg	249
3/7/2018	Oxycodone	10 mg	234

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Date	Drug Name	Strength	Quantity
3/7/2018	Klonopin	1 mg	45
3/7/2018	Zanaflex	4 mg	219
3/28/2018	Oxycodone	10 mg	234
3/28/2018	Klonopin	1 mg	30
3/28/2018	Zanaflex	4 mg	219
4/18/2018	Oxycodone	10 mg	234
4/18/2018	Klonopin	1 mg	30
4/18/2018	Zanaflex	4 mg	219
5/9/2018	Oxycodone	10 mg	210
5/9/2018	Klonopin	1 mg	30
5/9/2018	Zanaflex	4 mg	219
5/30/2018	Oxycodone	10 mg	210
5/30/2018	Klonopin	1 mg	30
5/30/2018	Zanaflex	4 mg	200
6/20/2018	Oxycodone	10 mg	200
6/20/2018	Klonopin	1 mg	30
6/20/2018	Zanaflex	4 mg	200
7/11/2018	Oxycodone	10 mg	200
7/11/2018	Klonopin	1 mg	30
7/11/2018	Zanaflex	4 mg	190

38. During this period, in his progress note for a clinical encounter with Patient A on or about April 18, 2018, Respondent documented that “[he] had planned to cut back the oxy[codone]. [Patient A’s spouse] has asked [Respondent] to just cut back the Klonopin, which [Respondent] will do...” In fact, Respondent failed to reduce the amount of either the oxycodone or Klonopin prescribed to Patient A on or about April 18, 2018.

39. During this period, in a progress note for an encounter on or about May 9, 2018, Respondent documented that Patient A’s spouse, without Patient A present, presented to Respondent. On or about May 9, 2018, Respondent provided prescriptions for Patient A for oxycodone, Klonopin and Zanaflex.

40. On or about July 25, 2018, Respondent received a call from Patient A and her spouse in which they represented that Patient A’s medication had been stolen. In response, Respondent

1 issued to Patient A prescriptions for purported one-week supplies of approximately 50 oxycodone
2 10 mg tablets and 50 Zanaflex 4 mg pills.

3 41. On or about August 1, 2018, Respondent issued to Patient A prescriptions for
4 purported one-month supplies of approximately 190 oxycodone 10 mg tablets, 30 Klonopin 1 mg
5 tablets, and 190 Zanaflex 4 mg pills.

6 42. In a progress note for an encounter on or about August 20, 2018, Respondent
7 documented that Patient A's spouse again presented to Respondent, without Patient A present.
8 Respondent documented that he explained to Patient A's spouse that Respondent has to see
9 Patient A in person, but nonetheless provided temporary prescriptions, for approximately
10 30 oxycodone 10 mg tablets, 30 Klonopin 1 mg tablets, and 30 Zanaflex 4 mg pills, that would be
11 deducted from Patient A's purported total monthly prescriptions.

12 43. In a progress note for a clinical encounter on or about August 22, 2018; Respondent
13 documented that Patient A presented to his office with her spouse, and that Respondent issued to
14 Patient A prescriptions for approximately 160 oxycodone 10 mg tablets and 160 Zanaflex 4 mg
15 pills.

16 44. In a progress note for an encounter on or about September 6, 2018, Respondent
17 documented that Patient A's spouse again presented to Respondent, without Patient A present.
18 Respondent documented that Patient A's spouse represented that Patient A was at another
19 facility's emergency room for a flare up of colitis. Respondent further documented that
20 Patient A's spouse wanted to obtain an extra week's worth of medication in anticipation of
21 Patient A's discharge from the emergency room because Patient A had increased her usage of the
22 oxycodone tablets to approximately 10 tablets per day and had run out of oxycodone early.
23 Respondent documented that he did not provide the requested prescription during this encounter:

24 45. On or about September 14, 2018, Respondent issued for Patient A prescriptions for
25 approximately 42 oxycodone 10 mg tablets and 30 Zanaflex 4 mg pills.

26 46. In a progress note for a clinical encounter on or about September 19, 2018,
27 Respondent documented that Patient A presented to him, with her spouse present. Respondent
28 further documented that Patient A had been discharged after a four-day hospitalization for severe

1 colitis, and that Respondent had given Patient A's spouse a short-term prescription the previous
2 week because Patient A had run out early. Respondent documented that he advised Patient A that
3 he was prescribing her 180 oxycodone tablets per month, which was six per day. Respondent
4 documented that Patient A's spouse told Respondent that Patient A is taking eight oxycodone
5 tablets per day.

6 47. In fact, on or about September 19, 2018, Respondent issued to Patient A
7 a prescription for approximately 190 oxycodone 10 mg tablets, as well as for additional
8 medications including, but not limited to, 30 Klonopin 1 mg tablets and 180 Zanaflex 4 mg pills.

9 48. On or about September 24, 2018, Respondent received a notification from an
10 insurance carrier stating, among other things, that Patient A filled prescriptions from Respondent
11 in the month of August 2018 totaling approximately 380 oxycodone 10 mg tablets, and filled a
12 prescription issued by a health care provider other than Respondent for approximately 50
13 oxycodone 10 mg tablets on or about September 10, 2018.

14 49. On or about October 10, 2018, Respondent issued to Patient A prescriptions for
15 medications including, but not limited to, approximately 190 oxycodone 10 mg tablets,
16 30 Klonopin 1 mg tablets, and 180 Zanaflex 4 mg pills.

17 50. In his progress note for a clinical encounter with Patient A on or about November 1,
18 2018, Respondent documented that he had helped to set up an appointment with a "pain doctor."
19 Respondent documented that the pain doctor had requested some of Patient A's medical records
20 from Respondent but that Patient A was not willing to provide such records, or authorization for
21 their release, until she met the pain doctor.

22 51. On or about November 1, 2018, Respondent issued to Patient A prescriptions for
23 purported monthly supplies of medications including, but not limited to, approximately
24 190 oxycodone 10 mg tablets, 30 Klonopin 1 mg tablets, and 180 Zanaflex 4 mg pills.

25 52. On or about December 5, 2018, Patient A presented to Respondent. In his progress
26 note for this clinical encounter, Respondent documented that he had reviewed the CURES
27 database, which contained entries indicating that Patient A had received Klonopin, oxycodone,

28 ///

1 and fentanyl patches from another healthcare provider on November 11, 2018. Respondent
2 documented that he explained to Patient A that this clinical encounter would be their final one.

3 53. On or about December 5, 2018, Respondent issued to Patient A prescriptions for
4 medications including, but not limited to, approximately 210 oxycodone 10 mg tablets,
5 30 Klonopin 1 mg tablets, and 180 Zanaflex 4 mg pills.

6 54. At or near the outset of his prescribing of controlled substances or muscle relaxants to
7 Patient A, Respondent failed to adequately perform or document patient evaluation, assessment
8 and risk stratification for Patient A.

9 55. On multiple occasions during the course of his prescribing of controlled substances to
10 Patient A, Respondent failed to adequately document details regarding the controlled substances
11 being prescribed or the rationale for prescribing such medications, or the prescribed dosages.

12 56. During the course of his prescribing of controlled substances to Patient A,
13 Respondent failed to adequately establish or document treatment goals and outcomes for
14 Patient A.

15 57. During the course of Respondent's prescribing of controlled substances to Patient A,
16 Respondent failed to adequately obtain or maintain records from other healthcare providers that
17 had previously provided pain management treatment to Patient A, or were treating Patient A
18 contemporaneously with Respondent.

19 58. During the course of Respondent's prescribing of controlled substances to Patient A,
20 Respondent failed to adequately document discussions with other healthcare providers to
21 Patient A.

22 59. During the course of Respondent's prescribing of controlled substances to Patient A,
23 Respondent failed to adequately review or document review of the CURES database for
24 controlled substance prescriptions filled to Patient A.

25 60. During the course of Respondent's prescribing of controlled substances to Patient A,
26 Respondent failed to adequately review or document review of toxicology drug testing for
27 Patient A.

28 ////

1 61. During the course of Respondent's prescribing of controlled substances to Patient A,
2 Respondent failed to adequately conduct physical examinations of Patient A.

3 62. During the course of Respondent's prescribing of controlled substances to Patient A,
4 Respondent failed to adequately conduct or document reassessment for the continuation, revision
5 or termination of the controlled substances prescribed to Patient A.

6 63. During the course of Respondent's prescribing of controlled substances to Patient A,
7 Respondent failed to adequately obtain or document vital signs for Patient A.

8 64. During the course of Respondent's prescribing of controlled substances to Patient A,
9 Respondent failed to adequately discuss or document discussing with Patient A the risks
10 associated with the use of opioids in combination with benzodiazepines.

11 65. During the course of Respondent's prescribing of controlled substances to Patient A,
12 Respondent failed to adequately consider or document consideration of prescribing Narcan to
13 Patient A.

14 66. During the course of Respondent's care and treatment of Patient A, Respondent failed
15 to adequately assess or document assessment of the effects of his chronic prescribing of opioids,
16 benzodiazepines, or muscle relaxants, or any combination thereof, to Patient A.

17 67. During the course of Respondent's care and treatment of Patient A, Respondent failed
18 to adequately assess or document assessment of Patient A for aberrant medication use or
19 substance use disorder.

20 68. During the course of Respondent's care and treatment of Patient A, Respondent
21 prescribed chronic high-doses of oxycodone, Klonopin, and Zanaflex without adequate medical
22 indication.

23 69. Respondent's inappropriate prescribing of chronic high doses of opioids and
24 benzodiazepines to Patient A resulted in harm to Patient A including, but not limited to,
25 worsening drowsiness, deterioration of cognition, cycles of vomiting and diarrhea, flares of
26 colitis, constipation, hypotension with syncope, opioid-induced hyperanalgesia, or any
27 combination thereof.

28 ///

1 Respondent further documented that he increased Patient B's prescribed monthly supply of
2 Klonopin 2 mg tablets from approximately 60 tablets to 90 tablets (i.e., from approximately 4 mg
3 to 6 mg per day).

4 75. In or about January 2015 to March 2015, Respondent issued multiple prescriptions to
5 Patient B including, but not limited to, prescriptions corresponding to approximately 75 mg per
6 day of Adderall XR and 4 to 6 mg per day of Klonopin.

7 76. In his progress note for a clinical encounter with Patient B on or about March 12,
8 2015, Respondent documented that Patient B was scheduled for gastric bypass surgery in April
9 2015.

10 77. The CURES database lists two controlled substance prescriptions, for tramadol¹¹ and
11 Lortab,¹² issued by healthcare providers other than Respondent and filled to Patient B in or about
12 March or April 2015.

13 78. The CURES database lists multiple controlled substance prescriptions issued by
14 Respondent and filled to Patient B in or about April 9, 2015 to June 15, 2015:

Date Filled	Drug Name	Strength	Quantity	Days Supply
4/9/2015	Clonazepam	2 mg	90	30
5/18/2015	Clonazepam	2 mg	90	30
5/20/2015	Adderall XR	15 mg	30	30
5/21/2015	Adderall XR	30 mg	60	30
6/15/2015	Clonazepam	2 mg	90	30

15
16
17
18
19
20
21 79. Respondent's medical records for Patient B contain no record of any clinical
22 encounters with Patient B between March 13, 2015 and June 15, 2015, inclusive, or any
23 prescriptions issued during such period.

24 80. On or about June 29, 2015, Patient B presented to Respondent. In his progress note
25 for this clinical encounter, Respondent documented that it was "the first time the patient [had]

26 ¹¹ Tramadol is a Schedule IV controlled substance pursuant to 21 C.F.R., § 1308.14 and a
27 dangerous drug pursuant to Business and Professions Code section 4022.

28 ¹² Lortab is a brand name for the drug combination of hydrocodone and acetaminophen, a
Schedule II controlled substance pursuant to Health and Safety Code section 11055,
subdivision (b), and a dangerous drug pursuant to Business and Professions Code section 4022.

1 seen [him] in quite some time.” Respondent further documented that she had been in the hospital,
2 gotten septic, and had had a bowel obstruction.

3 81. In or about June 29, 2015 to January 2016, Respondent issued multiple prescriptions
4 to Patient B including, but not limited to, prescriptions corresponding to approximately 75 mg per
5 day of Adderall XR and 4 to 6 mg per day of Klonopin.

6 82. In or about October or November 2015, Respondent issued to Patient B a prescription
7 for a purported one-month supply of approximately 30 Belsomra 20 mg tablets.¹³ Patient B filled
8 or refilled the Belsomra prescription on or about November 5, 2015, December 8, 2015, and
9 January 23, 2016.

10 83. In his progress note for a clinical encounter with Patient B on or about February 4,
11 2016, Respondent documented that Patient B was “having a heck of a time sleeping” and that she
12 had taken Klonopin, Belsomra, and Zyprexa¹⁴ “and not slept.”

13 84. In or about February 2016 to December 2016, Respondent continued to issue
14 prescriptions to Patient B including, but not limited to, prescriptions corresponding to
15 approximately 75 mg per day of Adderall XR and 4 to 6 mg per day of Klonopin.

16 85. During this period, in a progress note for a clinical encounter with Patient B on or
17 about October 20, 2016, Respondent documented that “[t]he patient [was] dealing with a lot of
18 problems with gallstones.... She’s not taking pain meds, which [Respondent was] happy about.”

19 86. In fact, the CURES database lists prescriptions issued by healthcare providers other
20 than Respondent and filled to Patient B for oxycodone HCL/acetaminophen 10/325 mg or
21 oxycodone HCL 5 mg on or about October 15, October 28, and November 15, 2016.

22 87. In a telephone note dated January 12, 2017, Respondent documented that “[Patient B
23 was] very agitated. She’s having suicidal thoughts. She doesn’t feel safe. She is willing to
24 contract for safety.” Respondent documented that he prescribed approximately 20 Zyprexa 15 mg

25 ////

26 ¹³ Belsomra is a brand name for suvorexant, a Schedule IV controlled substance pursuant
27 to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to
Business and Professions Code section 4022. It is commonly used to treat insomnia.

28 ¹⁴ Zyprexa is a brand name for olanzapine, a psychotropic agent and dangerous drug
pursuant to Business and Professions Code section 4022.

1 pills and asked Patient B to start with taking half a pill and check in with Respondent. Respondent
2 documented that Patient B would see her psychologist in the morning.

3 88. On or about January 12, 2017, Respondent failed to adequately perform or document
4 an MSE or a suicide risk assessment of Patient B.

5 89. On or after January 12, 2017, Respondent failed to adequately consult or document
6 consultation with any other healthcare provider to Patient B, or schedule a follow-up appointment
7 with Patient B within a time frame consistent with her acute presentation on or about January 12,
8 2017.

9 90. In or about January 2017 to December 2017, Respondent continued to issue
10 prescriptions to Patient B including, but not limited to, prescriptions corresponding to
11 approximately 75 mg per day of Adderall XR and 4 to 6 mg per day of Klonopin.

12 91. The CURES database lists a prescription issued by a healthcare provider other than
13 Respondent, and filled to Patient B on or about December 15, 2017, for approximately six
14 tramadol 50 mg tablets.

15 92. In or about January 2018 to July 2018, Respondent continued to issue prescriptions to
16 Patient B including, but not limited to, prescriptions corresponding to approximately 75 mg per
17 day of Adderall XR and 4 to 6 mg per day of Klonopin.

18 93. During the course of Respondent's prescribing of Klonopin to Patient B in or around
19 January 2015 to July 2018, Respondent failed to adequately discuss or document discussing with
20 Patient B the risks of benzodiazepine use in combination with opioids or opiates, or the
21 possibility of prescribing Narcan to Patient B.

22 94. On multiple occasions during the course of Respondent's care and treatment of
23 Patient B in or around January 2015 to July 2018, Respondent failed to adequately obtain or
24 document obtaining vital signs including, but not limited to, blood pressure or heart rate from
25 Patient B.

26 95. During the course of Respondent's prescribing of controlled substances to Patient B
27 in or around January 2015 to July 2018, Respondent failed to adequately review or document
28 review of the CURES database for controlled substance prescriptions filled to Patient B.

1 96. During the course of Respondent's prescribing of controlled substances to Patient B
2 in or around January 2015 to July 2018, Respondent failed to adequately review or document
3 review of toxicology drug testing for Patient B.

4 97. On multiple occasions during the course of Respondent's care and treatment of
5 Patient B in or about January 2015 to July 2018, Respondent failed to adequately document a
6 clinical encounter with Patient B including, but not limited to, failing to adequately document
7 subjective impressions or assessments of the patient's psychiatric status, the basis for continuation
8 or modification of treatment, a psychiatric diagnosis or diagnoses, Respondent's treatment plan,
9 or any combination thereof.

10 98. On multiple occasions during the course of Respondent's care and treatment of
11 Patient B in or about January 2015 to July 2018, Respondent failed to adequately perform or
12 document an MSE during a clinical encounter with Patient B.

13 99. During the course of Respondent's care and treatment of Patient B in or around
14 January 2015 to July 2018, Respondent failed to adequately discuss or document discussion with
15 Patient B's psychologist regarding Patient B's mental health treatment.

16 100. During the course of Respondent's care and treatment of Patient B in or about
17 January 2015 to July 2018, Respondent failed to adequately assess or document assessment of his
18 ongoing chronic prescribing of Klonopin to Patient B.

19 101. On multiple occasions during the course of Respondent's care and treatment of
20 Patient B in or around January 2015 to July 2018, Respondent increased the dosage or quantity of
21 Klonopin prescribed to Patient B in response to an increase in one or more of the patient's PTSD
22 symptoms. Benzodiazepines, such as Klonopin, are contraindicated for PTSD.

23 102. During the course of Respondent's prescribing of Adderall to Patient B in or around
24 January 2015 to July 2018, Respondent failed to adequately assess or document assessment of
25 whether his chronic, high-dose prescribing of Adderall was contributing to Patient B's complaints
26 of insomnia.

27 ///

28 ///

1 103. Respondent committed gross negligence in the course of his care and treatment of
2 Patient B including, but not limited to, failing to adequately:

3 (a) Maintain medical records for Patient B.

4 (b) Perform evaluation, assessment and risk stratification of Patient B while
5 prescribing her multiple controlled substances.

6 (c) Complete and document a suicide risk assessment for Patient B in or around
7 January 2017.

8 **SECOND CAUSE FOR DISCIPLINE**

9 **(Repeated Acts of Negligence)**

10 104. Respondent Michael Theodore Lardon, M.D. has further subjected his Physician's
11 and Surgeon's Certificate No. A 48664 to disciplinary action under sections 2227 and 2234, as
12 defined by section 2234, subdivision (c), of the Code in that he committed repeated negligent acts
13 in his care and treatment of one or more patients as more particularly alleged in paragraphs 9 to
14 103, above, which are hereby incorporated by reference and realleged as if fully set forth herein.

15 **THIRD CAUSE FOR DISCIPLINE**

16 **(Prescribing, Dispensing, or Furnishing of a Dangerous Drug without an
17 Appropriate Prior Examination and a Medical Indication)**

18 105. Respondent Michael Theodore Lardon, M.D. has further subjected his Physician's
19 and Surgeon's Certificate No. A 48664 to disciplinary action under sections 2227 and 2234, as
20 defined by section 2242, of the Code in that he prescribed, dispensed, or furnished a dangerous
21 drug on one or more occasions without an appropriate prior examination and medical indication
22 as more particularly alleged in paragraphs 9 to 104, above, which are hereby incorporated by
23 reference and realleged as if fully set forth herein.

24 **FOURTH CAUSE FOR DISCIPLINE**

25 **(Repeated Acts of Clearly Excessive Prescribing)**

26 106. Respondent Michael Theodore Lardon, M.D. has further subjected his Physician's
27 and Surgeon's Certificate No. A 48664 to disciplinary action under sections 2227 and 2234, as
28 defined by section 725, of the Code in that he committed repeated acts of clearly excessive

1 prescribing, furnishing, dispensing or administering of a drug or treatment as more particularly
2 alleged in paragraphs 9 to 104, above, which are hereby incorporated by reference and realleged
3 as if fully set forth herein.

4 **FIFTH CAUSE FOR DISCIPLINE**

5 **(Failure to Maintain Adequate and Accurate Records)**

6 107. Respondent Michael Theodore Lardon, M.D. has further subjected his Physician's
7 and Surgeon's Certificate No. A 48664 to disciplinary action under sections 2227 and 2234, as
8 defined by section 2266, of the Code in that he failed to maintain adequate and accurate records
9 relating to his provision of services to one or more patients as more particularly alleged in
10 paragraphs 9 to 104, above, which are hereby incorporated by reference and realleged as if fully
11 set forth herein.

12 **SIXTH CAUSE FOR DISCIPLINE**

13 **(Violation of the Medical Practice Act)**

14 108. Respondent Michael Theodore Lardon, M.D. has further subjected his Physician's
15 and Surgeon's Certificate No. A 48664 to disciplinary action under sections 2227 and 2234, as
16 defined by section 2234, subdivision (a), of the Code in that he violated or attempted to violate,
17 directly or indirectly, any provision of the Medical Practice Act as more particularly alleged in
18 paragraphs 9 to 107, above, which are hereby incorporated by reference and realleged as if fully
19 set forth herein.

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate No. A 48664, issued to Respondent Michael Theodore Lardon, M.D.;
2. Revoking, suspending or denying approval of Respondent Michael Theodore Lardon, M.D.'s authority to supervise physician assistants and advanced practice nurses;
3. Ordering Respondent Michael Theodore Lardon, M.D., if placed on probation, to pay the Board the costs of probation monitoring; and
4. Taking such other and further action as deemed necessary and proper.

DATED: JUL 30 2020



WILLIAM PRASIFKA
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant